Drugs / XZP-5809
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04622072 | Nov 2020 → May 2021 | non-small cell lung carcinoma | Sihuan Pharmaceutical Holdings Group Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZP-5809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622072 ↗ |